Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.
Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt.
Int Immunopharmacol. 2024 Jul 30;136:112395. doi: 10.1016/j.intimp.2024.112395. Epub 2024 Jun 4.
Asthma is a long-term disease that causes airways swelling and inflammation and in turn airway narrowing. AdipoRonis an orally active synthetic small molecule that acts as a selective agonist at theadiponectin receptor 1 and 2. The aim of the current study is to delineate the protective effect and the potential underlying mechanism ofadipoRon inairway inflammationinduced byovalbumin (OVA) in comparison withdexamethasone. Adult maleSwiss Albino micewere sensitized to OVA on days 0 and 7, then challenged with OVA on days 14, 15 and 16. AdipoRon was administered orally for 6 days starting from the 11 day till the 16 and 1 h prior to OVA in the challenge days. Obtained results from asthmatic control group showed a significant decrease in serum adiponectin concentration, an increase in inflammatory cell counts inthe bronchoalveolar lavage fluid(BALF), CD68 protein expression, inflammatory cytokine concentration and oxidative stress as well. Administration of adipoRon enhanced antioxidant mechanisms limiting oxidative stress by significantly increasing reduced glutathione (GSH) pulmonary content, decreasing serum lactate dehydrogenase (LDH) together with malondialdehyde (MDA) significant reduction in lung tissue. In addition, it modulated the levels of serum immunoglobulin E (IgE), pro-inflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-4, IL-13, nuclear factor kappa B (NF-κB) and the anti-inflammatory one IL-10 improving lung inflammation as revealed by histopathological evaluation. Furthermore, lung tissue expression of nuclear factor erythroid 2-related factor (Nrf2) and 5'AMP-activated protein kinase (AMPK) were significantly increased adipoRon. Notably, results of adipoRon received group were comparable to those of dexamethasone group. In conclusion, our study demonstrates that adipoRon can positively modulate adiponectin expression with activation of AMPK pathway and subsequent improvement in inflammatory and oxidative signaling.
哮喘是一种长期疾病,会导致气道肿胀和炎症,进而导致气道狭窄。AdipoRon 是一种口服活性的合成小分子,作为脂联素受体 1 和 2 的选择性激动剂。本研究旨在描绘 AdipoRon 在卵清蛋白(OVA)诱导的气道炎症中的保护作用及其潜在机制,并与地塞米松进行比较。成年雄性瑞士白化病小鼠在第 0 天和第 7 天对 OVA 致敏,然后在第 14、15 和 16 天用 OVA 进行挑战。AdipoRon 从第 11 天开始口服给药 6 天,直至第 16 天,并在挑战日的 1 小时前给药。哮喘对照组的结果显示,血清脂联素浓度显著降低,支气管肺泡灌洗液(BALF)中的炎症细胞计数增加,CD68 蛋白表达、炎症细胞因子浓度和氧化应激增加。AdipoRon 的给药增强了抗氧化机制,通过显著增加还原型谷胱甘肽(GSH)的肺含量、降低血清乳酸脱氢酶(LDH)和丙二醛(MDA)的含量,从而限制了氧化应激。此外,它还调节了血清免疫球蛋白 E(IgE)、促炎细胞因子肿瘤坏死因子(TNF)-α、白细胞介素(IL)-4、IL-13、核因子 kappa B(NF-κB)和抗炎细胞因子 IL-10 的水平,改善了肺炎症,如组织病理学评估所示。此外,AdipoRon 还显著增加了核因子红细胞 2 相关因子(Nrf2)和 5'AMP 激活蛋白激酶(AMPK)在肺组织中的表达。值得注意的是,AdipoRon 组的结果与地塞米松组的结果相当。总之,我们的研究表明,AdipoRon 可以通过激活 AMPK 途径和随后改善炎症和氧化信号来积极调节脂联素的表达。